- Home
- ELVN vs SONO Comparison
ELVN vs SONO Comparison
Compare ELVN & SONO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- SONO
- Stock Information
- Founded
- ELVN 2016
- SONO 2002
- Country
- ELVN United States
- SONO United States
- Employees
- ELVN N/A
- SONO N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- SONO Consumer Electronics/Video Chains
- Sector
- ELVN Health Care
- SONO Consumer Discretionary
- Exchange
- ELVN Nasdaq
- SONO Nasdaq
- Market Cap
- ELVN 1.3B
- SONO 1.4B
- IPO Year
- ELVN 2020
- SONO 2018
- Fundamental
- Price
- ELVN $25.91
- SONO $13.50
- Analyst Decision
- ELVN Strong Buy
- SONO Buy
- Analyst Count
- ELVN 4
- SONO 2
- Target Price
- ELVN $36.75
- SONO $17.50
- AVG Volume (30 Days)
- ELVN 244.8K
- SONO 2.1M
- Earning Date
- ELVN 11-13-2024
- SONO 11-13-2024
- Dividend Yield
- ELVN N/A
- SONO N/A
- EPS Growth
- ELVN N/A
- SONO N/A
- EPS
- ELVN N/A
- SONO N/A
- Revenue
- ELVN N/A
- SONO $1,518,056,000.00
- Revenue This Year
- ELVN N/A
- SONO N/A
- Revenue Next Year
- ELVN N/A
- SONO $14.58
- P/E Ratio
- ELVN N/A
- SONO N/A
- Revenue Growth
- ELVN N/A
- SONO N/A
- 52 Week Low
- ELVN $9.80
- SONO $10.23
- 52 Week High
- ELVN $30.03
- SONO $19.76
- Technical
- Relative Strength Index (RSI)
- ELVN 41.12
- SONO 54.86
- Support Level
- ELVN $24.69
- SONO $12.30
- Resistance Level
- ELVN $26.48
- SONO $15.89
- Average True Range (ATR)
- ELVN 1.38
- SONO 0.72
- MACD
- ELVN -0.32
- SONO -0.10
- Stochastic Oscillator
- ELVN 28.35
- SONO 33.43
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About SONO Sonos Inc.
Sonos Inc is engaged in providing home sound systems. The company's product profile includes speaker sets and other accessories like boost, mounts, stands, and cables and networking. Geographically, the company operates in the Americas, Europe, the Middle East and Africa, and the Asia Pacific. Generating a majority of its revenue from the Americas.